Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes

VR Aroda, U Erhan, P Jelnes, JJ Meier… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim Glucagon‐like peptide‐1 receptor agonists improve glycaemic control: some are now
available as oral and subcutaneous formulations, and some have indications for reducing …
被引用次数：21 相关文章

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.

VR Aroda, U Erhan, P Jelnes, JJ Meier… - Diabetes, Obesity & …, 2023 - europepmc.org
Aims Glucagon-like peptide-1 receptor agonists improve glycaemic control: some are now
available as oral and subcutaneous formulations, and some have indications for reducing …

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes

VR Aroda, U Erhan, P Jelnes, JJ Meier… - Diabetes, Obesity …, 2023 - research.regionh.dk
AIM: Glucagon-like peptide-1 receptor agonists improve glycaemic control: some are now
available as oral and subcutaneous formulations, and some have indications for reducing …

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes

VR Aroda, U Erhan, P Jelnes… - Diabetes, obesity & …, 2023 - pubmed.ncbi.nlm.nih.gov
Aim Glucagon-like peptide-1 receptor agonists improve glycaemic control: some are now
available as oral and subcutaneous formulations, and some have indications for reducing …

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.

VR Aroda, U Erhan, P Jelnes, JJ Meier… - Diabetes, Obesity & …, 2023 - search.ebscohost.com
Abstract Aim: Glucagon‐like peptide‐1 receptor agonists improve glycaemic control: some
are now available as oral and subcutaneous formulations, and some have indications for …